Chimeric antigen receptor T-cell therapy for refractory systemic autoimmune rheumatological diseases

Mads Lamm Larsen; Anne Voss; Christoffer Tandrup Holst Nielsen; Ellen-Margrethe Hauge; Mikkel Faurschou; Anne Troldborg

doi:10.61409/V06240429

Chimeric antigen receptor T-cell therapy for refractory systemic autoimmune rheumatological diseases

Translated title of the contribution: Not Available

Mads Lamm Larsen, Anne Voss, Christoffer Tandrup Holst Nielsen, Ellen-Margrethe Hauge, Mikkel Faurschou, Anne Troldborg

Department for Rheumatology and Spine Diseases

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy is emerging as a novel treatment for systemic autoimmune rheumatic diseases. To date, CAR-T therapy in rheumatology has been reported only in case studies and conference abstracts, but clinical trial results are forthcoming. Current evidence indicates a rapid and highly effective therapeutic response with a favourable side effect profile, suggesting that CD19 CAR-T therapy could be beneficially established for these conditions. Initially, CAR-T therapy appears relevant for a select group of severe, treatment-resistant rheumatic diseases.

Translated title of the contribution	Not Available
Original language	Danish
Article number	V06240429
Journal	Ugeskrift for Laeger
Volume	186
Issue number	47
ISSN	0041-5782
DOIs	https://doi.org/10.61409/V06240429
Publication status	Published - 18 Nov 2024

Access to Document

10.61409/V06240429Licence: CC BY-NC-ND

Cite this

@article{ea66b086b7f64d90b75a2b988cf2ab8d,

title = "Chimeric antigen receptor T-cell therapy for refractory systemic autoimmune rheumatological diseases",

abstract = "Chimeric antigen receptor T-cell (CAR-T) therapy is emerging as a novel treatment for systemic autoimmune rheumatic diseases. To date, CAR-T therapy in rheumatology has been reported only in case studies and conference abstracts, but clinical trial results are forthcoming. Current evidence indicates a rapid and highly effective therapeutic response with a favourable side effect profile, suggesting that CD19 CAR-T therapy could be beneficially established for these conditions. Initially, CAR-T therapy appears relevant for a select group of severe, treatment-resistant rheumatic diseases.",

keywords = "Humans, Rheumatic Diseases/therapy, Autoimmune Diseases/therapy, Receptors, Chimeric Antigen/immunology, Immunotherapy, Adoptive/methods, Receptors, Antigen, T-Cell/therapeutic use, Antigens, CD19/immunology, T-Lymphocytes/immunology, Lupus Erythematosus, Systemic/therapy",

author = "Larsen, {Mads Lamm} and Anne Voss and Nielsen, {Christoffer Tandrup Holst} and Ellen-Margrethe Hauge and Mikkel Faurschou and Anne Troldborg",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = nov,

day = "18",

doi = "10.61409/V06240429",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "47",

}

TY - JOUR

T1 - Chimeric antigen receptor T-cell therapy for refractory systemic autoimmune rheumatological diseases

AU - Larsen, Mads Lamm

AU - Voss, Anne

AU - Nielsen, Christoffer Tandrup Holst

AU - Hauge, Ellen-Margrethe

AU - Faurschou, Mikkel

AU - Troldborg, Anne

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/11/18

Y1 - 2024/11/18

N2 - Chimeric antigen receptor T-cell (CAR-T) therapy is emerging as a novel treatment for systemic autoimmune rheumatic diseases. To date, CAR-T therapy in rheumatology has been reported only in case studies and conference abstracts, but clinical trial results are forthcoming. Current evidence indicates a rapid and highly effective therapeutic response with a favourable side effect profile, suggesting that CD19 CAR-T therapy could be beneficially established for these conditions. Initially, CAR-T therapy appears relevant for a select group of severe, treatment-resistant rheumatic diseases.

AB - Chimeric antigen receptor T-cell (CAR-T) therapy is emerging as a novel treatment for systemic autoimmune rheumatic diseases. To date, CAR-T therapy in rheumatology has been reported only in case studies and conference abstracts, but clinical trial results are forthcoming. Current evidence indicates a rapid and highly effective therapeutic response with a favourable side effect profile, suggesting that CD19 CAR-T therapy could be beneficially established for these conditions. Initially, CAR-T therapy appears relevant for a select group of severe, treatment-resistant rheumatic diseases.

KW - Humans

KW - Rheumatic Diseases/therapy

KW - Autoimmune Diseases/therapy

KW - Receptors, Chimeric Antigen/immunology

KW - Immunotherapy, Adoptive/methods

KW - Receptors, Antigen, T-Cell/therapeutic use

KW - Antigens, CD19/immunology

KW - T-Lymphocytes/immunology

KW - Lupus Erythematosus, Systemic/therapy

UR - http://www.scopus.com/inward/record.url?scp=85210463089&partnerID=8YFLogxK

U2 - 10.61409/V06240429

DO - 10.61409/V06240429

M3 - Review

C2 - 39575908

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 47

M1 - V06240429

ER -

Chimeric antigen receptor T-cell therapy for refractory systemic autoimmune rheumatological diseases

Abstract

Access to Document

Other files and links

Fingerprint

Cite this